LFCR Relative Valuation
LFCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LFCR is overvalued; if below, it's undervalued.
Historical Valuation
Lifecore Biomedical Inc (LFCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.26 is considered Overvalued compared with the five-year average of -66.89. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.65 to 7.22 according to relative valuation methord. Compared to the current price of 7.79 USD , Lifecore Biomedical Inc is Overvalued By 7.91%.
Relative Value
Fair Zone
4.65-7.22
Current Price：7.79
7.91%
Overvalued
-9.30
PE
1Y
3Y
5Y
Trailing
Forward
21.33
EV/EBITDA
Lifecore Biomedical Inc. (LFCR) has a current EV/EBITDA of 21.33. The 5-year average EV/EBITDA is 23.48. The thresholds are as follows: Strongly Undervalued below -13.69, Undervalued between -13.69 and 4.89, Fairly Valued between 42.06 and 4.89, Overvalued between 42.06 and 60.65, and Strongly Overvalued above 60.65. The current Forward EV/EBITDA of 21.33 falls within the Historic Trend Line -Fairly Valued range.
-84.12
EV/EBIT
Lifecore Biomedical Inc. (LFCR) has a current EV/EBIT of -84.12. The 5-year average EV/EBIT is -2.98. The thresholds are as follows: Strongly Undervalued below -174.08, Undervalued between -174.08 and -88.53, Fairly Valued between 82.57 and -88.53, Overvalued between 82.57 and 168.12, and Strongly Overvalued above 168.12. The current Forward EV/EBIT of -84.12 falls within the Historic Trend Line -Fairly Valued range.
2.26
PS
Lifecore Biomedical Inc. (LFCR) has a current PS of 2.26. The 5-year average PS is 1.64. The thresholds are as follows: Strongly Undervalued below 0.71, Undervalued between 0.71 and 1.18, Fairly Valued between 2.11 and 1.18, Overvalued between 2.11 and 2.58, and Strongly Overvalued above 2.58. The current Forward PS of 2.26 falls within the Overvalued range.
22.34
P/OCF
Lifecore Biomedical Inc. (LFCR) has a current P/OCF of 22.34. The 5-year average P/OCF is 2.72. The thresholds are as follows: Strongly Undervalued below -13.33, Undervalued between -13.33 and -5.30, Fairly Valued between 10.75 and -5.30, Overvalued between 10.75 and 18.78, and Strongly Overvalued above 18.78. The current Forward P/OCF of 22.34 falls within the Strongly Overvalued range.
-34.64
P/FCF
Lifecore Biomedical Inc. (LFCR) has a current P/FCF of -34.64. The 5-year average P/FCF is -156.42. The thresholds are as follows: Strongly Undervalued below -2025.77, Undervalued between -2025.77 and -1091.10, Fairly Valued between 778.25 and -1091.10, Overvalued between 778.25 and 1712.93, and Strongly Overvalued above 1712.93. The current Forward P/FCF of -34.64 falls within the Historic Trend Line -Fairly Valued range.
Lifecore Biomedical Inc (LFCR) has a current Price-to-Book (P/B) ratio of 216.45. Compared to its 3-year average P/B ratio of 43.28 , the current P/B ratio is approximately 400.16% higher. Relative to its 5-year average P/B ratio of 26.71, the current P/B ratio is about 710.53% higher. Lifecore Biomedical Inc (LFCR) has a Forward Free Cash Flow (FCF) yield of approximately -4.65%. Compared to its 3-year average FCF yield of -13.57%, the current FCF yield is approximately -65.70% lower. Relative to its 5-year average FCF yield of -12.41% , the current FCF yield is about -62.48% lower.
216.45
P/B
Median3y
43.28
Median5y
26.71
-4.65
FCF Yield
Median3y
-13.57
Median5y
-12.41
Competitors Valuation Multiple
The average P/S ratio for LFCR's competitors is 1.79, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR) exhibits a P/S ratio of 2.26, which is 26.62% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LFCR increased by 5.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -4.70 to -6.13.
The secondary factor is the Revenue Growth, contributed 25.92%to the performance.
Overall, the performance of LFCR in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Lifecore Biomedical Inc (LFCR) currently overvalued or undervalued?
What is Lifecore Biomedical Inc (LFCR) fair value?
How does LFCR's valuation metrics compare to the industry average?
What is the current P/B ratio for Lifecore Biomedical Inc (LFCR) as of Dec 13 2025?
What is the current FCF Yield for Lifecore Biomedical Inc (LFCR) as of Dec 13 2025?
What is the current Forward P/E ratio for Lifecore Biomedical Inc (LFCR) as of Dec 13 2025?